NTRK2 and cancer: Given that E2-treated astrocytes activate both EGFR [16] and TrkB ligands on brain metastatic cancer cells and the majority of human BM are EGFR+, we assessed how EGFR and TrkB activation contributed to signaling and metastatic traits in EGFR+TrkB+ TNBC cells.